ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon Jun 01, 2016 4:36pm

74 Views

Post# 24924638

RE:Link for Conference call

Took me a while to get it sorted. I called from my landline and my cellphone - neither one worked. Called Bell and they passed the matter over to their technical division to try to figure out why. In the meanwhile I got the name of the conference call service and called them directly to get the alternate number which I forwarded to Scott. Hence the followup email.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload